Acerus Pharmaceuticals has received approval from Health Canada to market Natesto nasal gel as a testosterone replacement therapy in adult males with hypogonadism, and the product should be available in Canada by mid-2016, the company said.
Acerus President and CEO Tom Rossi said, “Natesto addresses many of the gaps with current testosterone replacement therapies. Health Canada’s approval of Natesto is a momentous event for Acerus, as it represents the opportunity to introduce a unique and novel option for the treatment of men with hypogonadism.”
Natesto was approved in the US in 2014 but Acerus’s US partner, Endo, recently said that it is “de-prioritizing” the product.
Read the Acerus press release.
